fremanezumab

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypertension, Raynaud's phenomenon

Local: injection site reactions

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

Solution for injection (prefilled syringes and autoinjectors): 225 mg/1.5 mL

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor, which reduces the neuroinflammatory and vasodilatory effects of CGRP.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: vascular headache suppressants

Pharmacologic Classification: monoclonal antibodies, calcitonin gene-related peptide receptor antagonists

Pharmacokinetics ⬆ ⬇

Absorption: Unknown.

Distribution: Minimal distribution to tissues.

Metabolism/Excretion: Degraded by enzymatic proteolysis into small peptides and amino acids.

Half-Life: 31 days.

Time/Action Profile ⬆ ⬇

( plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
SUBQ	unknown	5–7 days	1 mo

Patient/Family Teaching ⬆ ⬇

Explain the purpose and side effects. Instruct patient to take as directed. Administer missed doses as soon as possible and schedule next dose from date last dose administered. Educate patient and/or caregiver on correct technique for injection and disposal of equipment. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
Instruct patient to notify health care provider or call 911 immediately to seek medical care if signs/symptoms of hypersensitivity reaction occur.
Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care provider before taking other medications.
Rep: Advise women of reproductive potential to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Women with migraines may be at ↑ risk of preeclampsia and gestational hypertension during pregnancy. Inform patient of pregnancy exposure registry that monitors outcomes in women exposed to fremanezumab. Enrollment can be done by health care provider or patient by calling 1-833-927-2605 or visiting www.tevamigrainepregnancyregistry.com.